These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9864283)

  • 21. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys.
    Kurlan R; Kim MH; Gash DM
    Ann Neurol; 1991 Jun; 29(6):677-9. PubMed ID: 1892370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL; Cheetham SC; Jenner P
    Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
    Wichmann T; Kliem MA; DeLong MR
    Exp Neurol; 2001 Feb; 167(2):410-24. PubMed ID: 11161630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
    Mierau J; Schingnitz G
    Eur J Pharmacol; 1992 May; 215(2-3):161-70. PubMed ID: 1356788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MPTP-Induced pallidal lesions in rhesus monkeys.
    Zhang Z; Zhang M; Ai Y; Avison C; Gash DM
    Exp Neurol; 1999 Jan; 155(1):140-9. PubMed ID: 9918713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl.
    Bata-García JL; Villanueva-Toledo J; Gutiérrez-Ospina G; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
    Pharmacol Biochem Behav; 2007 Jan; 86(1):68-78. PubMed ID: 17250882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
    San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
    Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
    Gash DM; Zhang Z; Ai Y; Grondin R; Coffey R; Gerhardt GA
    Ann Neurol; 2005 Aug; 58(2):224-33. PubMed ID: 16049934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB; Lookingland KJ; Bédard PJ; Huff RM
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1248-56. PubMed ID: 15980060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
    Schneider JS; Lidsky TI; Hawks T; Mazziotta JC; Hoffman JM
    Brain Res; 1995 Feb; 672(1-2):112-7. PubMed ID: 7749732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramipexole protects against MPTP toxicity in non-human primates.
    Iravani MM; Haddon CO; Cooper JM; Jenner P; Schapira AH
    J Neurochem; 2006 Mar; 96(5):1315-21. PubMed ID: 16464239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of haloperidol at a low dose on the development of experimental parkinsonian syndrome].
    Korshunov AM; Voronina TA; Churiukanov VV; Iakhno NN
    Eksp Klin Farmakol; 1995; 58(6):7-9. PubMed ID: 8704620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Clarke CE; Boyce S; Robertson RG; Sambrook MA; Crossman AR
    J Neurol Sci; 1989 May; 90(3):307-14. PubMed ID: 2786926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.